Key facts
- It has raised $6.0M across 2 recorded rounds; the latest was Seed Round ($3.0M) in Feb 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS.
- Synlico has filed 4 Form Ds with the SEC since 2021, most recently Feb 2025 ($3.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Synlico
Funding rounds
2 roundsAbout Synlico
Developer of a causal AI platform intended to make cellular processes explainable, predictable, and engineerable. The company offers machine learning, causal discovery, and inference capabilities to map gene interactions and intervention effects, enabling researchers and clinicians working with patient-derived data to predict changes in cell behavior across diverse biological environments.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2021
- Employees
- 8
- Website
- synlico.com/
- Ownership
- Privately Held (backing)
Synlico doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synlico shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synlico in its N-PORT filings yet. We sweep new filings monthly.